CF Pharmtech’s ICF-004 cleared for clinical trials in China

Feb. 26, 2026

CF Pharmtech Inc. has announced approval from China’s National Medical Products Administration (NMPA) of an IND application filed by subsidiary Changfeng Suyue Pharmaceutical (Guangzhou) Co. Ltd. for ICF-004.

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Atai Therapeutics patents new 5-HT2 receptor agonists

BioWorld Science

Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.